Structure and properties of pharmacologically active polymers
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Although the concept of using pharmacologically active macromolecular compounds as drugs is still regarded with much skepticism for both theoretical and practical reasons, interest in this field has grown in recent years because of the opportunity to take advantage of the specific properties of polymeric materials. For low molecular weight drugs, changes in structure often lead to a loss of specific activity. On the other hand, the properties of macromolecular drugs depend on the structure of the polymer used and this can be varied over a wide range by the incorporation of comonomer units, by the application of polymer‐analogous reactions, or by related structural changes. A new model is presented for pharmacologically active polymers which incorporates the possibility for continuous variation in (a) solubility and toxicity, (b) fixation and removal of active material, and (c) body distribution. Using the new model as a guide, examples of the synthesis and study of the biological activity of various macromolecular drugs are presented in order to emphasize the importance of this cooperative effort between polymer research and therapeutic problems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The drug-polymer conjugates were introduced in the early work by Helmut Ringsdorf in 1970s to improve drug solubility, toxicity, and body biodistribution, which was followed by extensive studies on the development of drug-polymer conjugates [143, 144].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [144]
Citations
Cites
de Duve, C., & Wattiaux, R. (1966) · Annual Review of Physiology · doi:10.1146/annurev.ph.28.030166.002251 · Cited by 3,033
De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Chang, T. M. S. (1964) · Science · doi:10.1126/science.146.3643.524 · Cited by 1,011
Lysosomes in Biology and Pathology
Lagunoff, D. (1974) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1974.03230160059035 · Cited by 887
AN EXAMINATION OF THE CYTOTOXIC EFFECTS OF SILICA ON MACROPHAGES
Allison, A. C., Harington, J. S., & Birbeck, M. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.124.2.141 · Cited by 871
FACTOR-VIII COMPLEX AND ENDOTHELIAL DAMAGE
Boneu, B., Abbal, M., Plante, J., & Bierme, R. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92650-1 · Cited by 716
de Duve, C. (2008) · Novartis Foundation Symposia · doi:10.1002/9780470715314.ch1 · Cited by 473
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregoriadis, G., Swain, C. P., Wills, E. J., & Tavill, A. S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90682-5 · Cited by 401
Poly[N-(2-hydroxypropyl)methacrylamide]—I. Radical polymerization and copolymerization
Kopeček, J., & Baẑilová, H. (1973) · European Polymer Journal · doi:10.1016/0014-3057(73)90063-3 · Cited by 300
Ryser, H. J.-P. (1968) · Science · doi:10.1126/science.159.3813.390 · Cited by 288
Research works printed but not linked: 20
- Lee H., 1971, Handbook for Surgery and Artificial Organs
- Kabaiwanow W., 1972, Plaste Kaut., 19, 886
- Wessel W., 1971, Arzeim. Forsch., 21, 1468
- Ryser H. J. P., 1970, Proc. Fourth Int. Cong. Pharm., 3, 96
- 1965, Silikose Forsch., 6, 213
- Ferruti P., 1966, Med. Lav., 57, 481
- V.Hofmann dissertation University of Mainz 1975.
- Burger A., 1970, Medicinal Chemistry, 1185
- Donaruma L. G., 1974, Prog. Polym. Sci., 4, 18
- G.Franzmann dissertation University of Mainz 1975.
- H.Morawetzet al. in press.
- Ringsdorf H., 1967, Strahlentherapie, 132, 627
- Busch H., 1961, Cancer Res., 21, 271
- H.Ritter dissertation University of Mainz 1975.
- M.Przybylski dissertation University of Mainz 1975.
- Jacob S. W., 1971, Dimethylsulfoxide
- V.Hofmann H.Ringsdorf andG.Muacevic Makromol. Chem. in press.
- Jacques P. J., 1966, Rev. Quest. Sci., 27, 99
- Jacques P. J., 1969, Lysosomes in Biology and Pathology, 395
- Szekerke M., 1972, Neoplasma, 19, 211
Cited by
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
“10 ); the elaboration of the concepts of polymer–drug conjugate”
BackgroundPolymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
“Polymer–drug conjugates Ringsdorf had the idea of polymer–anticancer-drug conjugates in 1975 (Ref”
BackgroundGold Nanorods: From Synthesis and Properties to Biological and Biomedical Applications
Huang, X., Neretina, S., & El‐Sayed, M. A. (2009) · Advanced Materials · doi:10.1002/adma.200802789 · Cited by 1,921
Astruc, D., Boisselier, E., & Ornelas, C. (2010) · Chemical Reviews · doi:10.1021/cr900327d · Cited by 1,844
Polymers for Drug Delivery Systems
Liechty, W. B., Kryscio, D. R., Slaughter, B. V., & Peppas, N. A. (2010) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-073009-100847 · Cited by 1,608
Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications
Esfand, R., & Tomalia, D. A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01757-3 · Cited by 1,562
Ringsdorf, H., Schlarb, B., & Venzmer, J. (1988) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198801131 · Cited by 1,454
Self-citationDendrimers: synthesis, applications, and properties
Abbasi, E., Aval, S. F., Akbarzadeh, A., Milani, M., Nasrabadi, H. T., Joo, S. W., Hanifehpour, Y., Nejati-Koshki, K., & Pashaei-Asl, R. (2014) · Nanoscale Research Letters · doi:10.1186/1556-276x-9-247 · Cited by 1,279
“The strategy of coupling small molecules to polymeric scaffolds by covalent linkages to improve their pharmacological properties has been under experimental test for over three decades [43-46].”
BackgroundPolymer Therapeutics: Concepts and Applications
Haag, R., & Kratz, F. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502113 · Cited by 1,115
Bioapplications of RAFT Polymerization
Boyer, C., Bulmus, V., Davis, T. P., Ladmiral, V., Liu, J., & Perrier, S. (2009) · Chemical Reviews · doi:10.1021/cr9001403 · Cited by 1,015
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Nanotechnology applications in cancer
Nie, S., Xing, Y., Kim, G. J., & Simons, J. W. (2007) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.9.060906.152025 · Cited by 952
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 920
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Targeted delivery of low molecular drugs using chitosan and its derivatives
Park, J. H., Saravanakumar, G., Kim, K., & Kwon, I. C. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.10.003 · Cited by 821
“In 1975, Ringsdorf first proposed the concept of polymer–drug conjugates for delivering hydrophobic small molecular drugs to their site of action [65].”
BackgroundNanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Sinha, R., Kim, G. J., Nie, S., & Shin, D. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0141 · Cited by 801
The origins and evolution of “controlled” drug delivery systems
Hoffman, A. S. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.012 · Cited by 738
“10b) Independent of Davis and around that same time in the 1970s, Helmut Ringsdorf at the University of Mainz sketched the idea of a targeted, polymer-drug conjugate and published it in 1975 [14].”
BackgroundTorchilin, V. P. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00166-4 · Cited by 680
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
“The drug-polymer conjugates were introduced in the early work of Helmut Ringsdorf in the 1970s to improve drug solubility, toxicity, and body biodistribution, which was followed by extensive studies on the development of drug-polymer conjugates [143,144].”
BackgroundVasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 864
Bae, Y., & Kataoka, K. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.016 · Cited by 669
“Pioneers in 1970s suggested that drug delivery systems based on polymer science and supramolecular chemistry could overcome these limitations [67].”
BackgroundGreco, F., & Vicent, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.006 · Cited by 652
“Such nanoconstructs were first proposed in the 1970s [34], developed pre-clinically in the 1980s [35,36] and started entering the clinical pipeline in the 1990s [37–40, reviewed in this issue and in 41–44].”
BackgroundPolymer–drug conjugates: Progress in polymeric prodrugs
Khandare, J., & Minko, T. (2006) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2005.09.004 · Cited by 639
“In 1975, a rational model for pharmacologically active polymers was proposed by Ringsdorf—considered to be the pioneer of polymeric prodrug research [15].”
BackgroundPolymer–drug conjugation, recent achievements and general strategies
Pasut, G., & Veronese, F. M. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.008 · Cited by 616
Nanotechnology in Therapeutics: A Focus on Nanoparticles as A Drug Delivery System
Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T., & Tan, W. (2012) · Nanomedicine · doi:10.2217/nnm.12.87 · Cited by 606
Polymer Architecture and Drug Delivery
Qiu, L. Y., & Bae, Y. H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-9046-2 · Cited by 604
“A general model for polymerYdrug conjugation was proposed by Ringsdorf (9) in 1975, which was based on the combination of chemistry and biology and consisted of five main elements: polymeric backbone, drug, spacer, targeting group, and solubilizing moiety (Fig.”
Hyaluronic acid for anticancer drug and nucleic acid delivery
Dosio, F., Arpicco, S., Stella, B., & Fattal, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.011 · Cited by 596
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Supramolecular Drug‐Delivery Systems Based on Polymeric Core–Shell Architectures
Haag, R. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200301694 · Cited by 591
Smart hybrid materials by conjugation of responsive polymers to biomacromolecules
Cobo, I., Li, M., Sumerlin, B. S., & Perrier, S. (2015) · Nature Materials · doi:10.1038/nmat4106 · Cited by 574
Polymeric Conjugates for Drug Delivery
Larson, N., & Ghandehari, H. (2012) · Chemistry of Materials · doi:10.1021/cm2031569 · Cited by 580
HPMA copolymers: Origins, early developments, present, and future☆
Kopeček, J., & Kopečková, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.10.004 · Cited by 576
“Ringsdorf presented a clear summary of the field in 1975 [8].”
BackgroundEmerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications
Kannan, R. M., Nance, E., Kannan, S., & Tomalia, D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12280 · Cited by 542
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
PLGA-Based Nanoparticles as Cancer Drug Delivery Systems
Tabatabaei Mirakabad, F. S., Nejati-Koshki, K., Akbarzadeh, A., Yamchi, M. R., Milani, M., Zarghami, N., Zeighamian, V., Rahimzadeh, A., Alimohammadi, S., Hanifehpour, Y., et al. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.517 · Cited by 542
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
“Conceptualised by Ringsdorf (1975), it was envisioned that polymeric macromolecules can be conjugated to pharmacologically active agents by means of linkers that are stable in blood, but labile in the acidic and/or enzymatic conditions typical of, for example, the tumour microenvironment or certain…”
BackgroundEvolution of drug delivery systems: From 1950 to 2020 and beyond
Park, H., Otte, A., & Park, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.030 · Cited by 475
“A drug-polymer conjugate is a polymeric carrier having covalently bound drug molecules [61,62].”
BackgroundProdrug Strategies in Anticancer Chemotherapy
Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A. (2008) · ChemMedChem · doi:10.1002/cmdc.200700159 · Cited by 486
Polymeric anticancer drugs with pH-controlled activation
Ulbrich, K. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.040 · Cited by 494
Wang, Y., Xu, H., & Zhang, X. (2009) · Advanced Materials · doi:10.1002/adma.200803276 · Cited by 460
Polymer conjugates: nanosized medicines for treating cancer
Vicent, M. J., & Duncan, R. (2006) · Trends in Biotechnology · doi:10.1016/j.tibtech.2005.11.006 · Cited by 443
Polymer-drug conjugates: Recent development in clinical oncology
Li, C., & Wallace, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.009 · Cited by 436
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1668 · Cited by 435
Acid-degradable polymers for drug delivery: a decade of innovation
Binauld, S., & Stenzel, M. H. (2013) · Chemical Communications · doi:10.1039/c2cc36589h · Cited by 421
New Generation of Multifunctional Nanoparticles for Cancer Imaging and Therapy
Park, K., Lee, S., Kang, E., Kim, K., Choi, K., & Kwon, I. C. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200801655 · Cited by 432
Barz, M., Luxenhofer, R., Zentel, R., & Vicent, M. J. (2011) · Polymer Chemistry · doi:10.1039/c0py00406e · Cited by 418
Biomacromolecules as carriers in drug delivery and tissue engineering
Zhang, Y., Sun, T., & Jiang, C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.11.005 · Cited by 416
Polymer therapeutics-prospects for 21st century: The end of the beginning
Duncan, R., & Vicent, M. J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.012 · Cited by 412
“During the 1970s interest in the lysosomotropic polymer–drug conjugates, block copolymer micelles, and PEG-protein conjugates began to grow exponentially due to the pioneering work of De Duve and colleagues [19], Ringsdorf and colleagues [20,21], and Davis and colleagues [22,23] respectively.”
BackgroundPrecise nanomedicine for intelligent therapy of cancer
Chen, H., Gu, Z., An, H., Chen, C., Chen, J., Cui, R., Chen, S., Chen, W., Chen, X., Chen, X., et al. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9397-5 · Cited by 409
Poly(l-glutamic acid)–anticancer drug conjugates
Li, C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00045-5 · Cited by 414
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
“Ringsdorf H. Structure and properties of pharmacologically active polymers.”
InfluentialRingsdorf, H., Schlarb, B., & Venzmer, J. (1988) · Angewandte Chemie · doi:10.1002/ange.19881000111 · Cited by 399
Self-citationPolymeric nanostructured materials for biomedical applications
Tang, Z., He, C., Tian, H., Ding, J., Hsiao, B. S., Chu, B., & Chen, X. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.05.005 · Cited by 363
Polymeric micelles: nanocarriers for cancer-targeted drug delivery
Zhang, Y., Huang, Y., & Li, S. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0113-z · Cited by 367
Kuperkar, K., Patel, D., Atanase, L. I., & Bahadur, P. (2022) · Polymers · doi:10.3390/polym14214702 · Cited by 333
Polymer–drug conjugates: Origins, progress to date and future directions
Kopeček, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.014 · Cited by 347
YORK, A., KIRKLAND, S., & MCCORMICK, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.02.006 · Cited by 349
Evolution of macromolecular complexity in drug delivery systems
Kakkar, A., Traverso, G., Farokhzad, O. C., Weissleder, R., & Langer, R. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0063 · Cited by 320
Polyester Dendritic Systems for Drug Delivery Applications: Design, Synthesis, and Characterization
Ihre, H. R., Padilla De Jesús, O. L., Szoka, & Fréchet, J. M. J. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010102u · Cited by 332
Soluble synthetic polymers as potential drug carriers
Duncan, R., & Kopeček, J. (1984) · Advances in Polymer Science · doi:10.1007/3-540-12796-8_10 · Cited by 318
Polymeric Antitumor Agents on a Molecular and on a Cellular Level?
Gros, L., Ringsdorf, H., & Schupp, H. (1981) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198103051 · Cited by 318
Self-citationAdministration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
“Naturally, the linker should be stable in the bloodstream until the polymer conjugate reaches its destination [5,100,101].”
BackgroundThe enhanced permeability retention effect: a new paradigm for drug targeting in infection
Azzopardi, E. A., Ferguson, E. L., & Thomas, D. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks379 · Cited by 312
Polymer conjugates with anticancer activity
Putnam, D., & Kopeček, J. (1995) · Advances in Polymer Science · doi:10.1007/3540587888_14 · Cited by 315
Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action
Adhikari, H. S., & Yadav, P. N. (2018) · International Journal of Biomaterials · doi:10.1155/2018/2952085 · Cited by 313
“Furanoallocolchicinoid chitosan is a “smart” Ringsdorf ’s antitumor drug conjugate [196] that has been found to induce in vitro tubulin reorganization, cell cycle arrest, and more effective inhibition of the tumor cell proliferation in Wnt-1 breast tumor bearing mice [49, 75].”
BackgroundAnticancer Polymeric Nanomedicines
Tong, R., & Cheng, J. (2007) · Polymer Reviews · doi:10.1080/15583720701455079 · Cited by 310
“The covalent conjugation approach was first introduced by Ringsdorf in 1975.(40,41) In his postulated model of a polymer-drug conjugate, multiple drug molecules are bound to polymer side chains through covalent, cleavable bonds.”
BackgroundIntracellular targeting of polymer-bound drugs for cancer chemotherapy
NORI, A., & KOPECEK, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.006 · Cited by 303
Enzyme‐Responsive Polymer Hydrogel Particles for Controlled Release
Thornton, P. D., Mart, R. J., & Ulijn, R. V. (2007) · Advanced Materials · doi:10.1002/adma.200601784 · Cited by 293
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
Banerjee, S. S., Aher, N., Patil, R., & Khandare, J. (2012) · Journal of Drug Delivery · doi:10.1155/2012/103973 · Cited by 282
“Ringdorf was the first to propose the rational model for pharmacologically active polymers in 1975 [7].”
BackgroundInfluentialWatersoluble polymers in medicine
Bader, H., Ringsdorf, H., & Schmidt, B. (1984) · Die Angewandte Makromolekulare Chemie · doi:10.1002/apmc.1984.051230121 · Cited by 291
Self-citationMetal-containing and related polymers for biomedical applications
Yan, Y., Zhang, J., Ren, L., & Tang, C. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00026f · Cited by 283
Harnessing Endogenous Stimuli for Responsive Materials in Theranostics
Cook, A. B., & Decuzzi, P. (2021) · ACS Nano · doi:10.1021/acsnano.0c09115 · Cited by 262
Advances in Platinum Chemotherapeutics
Harper, B. W., Krause‐Heuer, A. M., Grant, M. P., Manohar, M., Garbutcheon‐Singh, K. B., & Aldrich‐Wright, J. R. (2010) · Chemistry – A European Journal · doi:10.1002/chem.201000148 · Cited by 267
Targeted drug conjugates: principles and progress
Garnett, M. C. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00227-7 · Cited by 262
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
Duncan, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.007 · Cited by 252
PEGylated polymers for medicine: from conjugation to self-assembled systems
Joralemon, M. J., McRae, S., & Emrick, T. (2010) · Chemical Communications · doi:10.1039/b920570p · Cited by 251
Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2-oxazoline)s
Gaertner, F. C., Luxenhofer, R., Blechert, B., Jordan, R., & Essler, M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.015 · Cited by 255
Molecular Self-Assembly and Supramolecular Chemistry of Cyclic Peptides
Song, Q., Cheng, Z., Kariuki, M., Hall, S. C. L., Hill, S. K., Rho, J. Y., & Perrier, S. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01291 · Cited by 242
Current drug research on PEGylation with small molecular agents
Li, W., Zhan, P., De Clercq, E., Lou, H., & Liu, X. (2013) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2012.07.006 · Cited by 232
“In addition, some investigators claim that the comparatively large molecular weight of PEG conjugation may impede the release of the small molecular weight drugs, so that they do not reach therapeutic concentrations at the target sites [23,27,28].”
BackgroundPolymer-coated long-circulating microparticulate pharmaceuticals
Torchilin, V. P. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006831 · Cited by 235
Effects of PEG conjugation on insulin properties
Hinds, K. D., & Kim, S. W. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00025-x · Cited by 240
Expert opinion: Responsive polymer nanoparticles in cancer therapy
Liechty, W. B., & Peppas, N. A. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.08.004 · Cited by 226
“The use of synthetic polymer-drug conjugates for drug delivery was first proposed in 1975 [37].”
BackgroundDuncan, R., & Vicent, M. J. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.12.005 · Cited by 230
Poly(2-oxazoline)s as materials for biomedical applications
de la Rosa, V. R. (2014) · Journal of Materials Science: Materials in Medicine · doi:10.1007/s10856-013-5034-y · Cited by 218
“The last few decades have seen significant expansion of polymer chemistry into the biomedical field, as Staudinger and Ringsdorf already envisioned many decades ago [1–3].”
BackgroundWater soluble polymers in tumor targeted delivery
Kopeček, J., Kopečková, P., Minko, T., Lu, Z.-R., & Peterson, C. M. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00330-3 · Cited by 227
Sood, A., Gupta, A., & Agrawal, G. (2021) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2021.100067 · Cited by 213
Polymer bioconjugates: Modern design concepts toward precision hybrid materials
Chen, C., Ng, D. Y. W., & Weil, T. (2020) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2020.101241 · Cited by 217
Murthy, N., Campbell, J., Fausto, N., Hoffman, A. S., & Stayton, P. S. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00099-3 · Cited by 221
Wani, W. A., Prashar, S., Shreaz, S., & Gómez-Ruiz, S. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.01.001 · Cited by 218
Chitosan Mediated Targeted Drug Delivery System: A Review
Patel, M. P., Patel, R. R., & Patel, J. K. (2010) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3jc7c · Cited by 214
Nanotechnology for targeted cancer therapy
Wang, M. D., Shin, D. M., Simons, J. W., & Nie, S. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.6.833 · Cited by 217
Liu, S., Maheshwari, R., & Kiick, K. L. (2009) · Macromolecules · doi:10.1021/ma801782q · Cited by 211
Multifunctional Poly(ethylene glycol)s
Obermeier, B., Wurm, F., Mangold, C., & Frey, H. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201100027 · Cited by 201
Polymer Therapeutics Designed for a Combination Therapy of Hormone‐Dependent Cancer
Vicent, M. J., Greco, F., Nicholson, R. I., Paul, A., Griffiths, P. C., & Duncan, R. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462960 · Cited by 199
Duncan, R., Gac-Breton, S., Keane, R., Musila, R., Sat, Y. N., Satchi, R., & Searle, F. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00328-5 · Cited by 195
Jung, K., Corrigan, N., Wong, E. H. H., & Boyer, C. (2022) · Advanced Materials · doi:10.1002/adma.202105063 · Cited by 183
Nanostructured hyaluronic acid-based materials for active delivery to cancer
Ossipov, D. A. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425241003730399 · Cited by 191
“The rationale for organic polymer carriers was formulated in 1975 by Ringsdorf [17] after the discovery of the ability of macromolecules to localize to lysosomes.”
BackgroundDuncan, R. (1999) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(99)00211-4 · Cited by 192
Metadata
- Authors
- Ringsdorf, H.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Ringsdorf, Helmut
- Venue
- Journal of Polymer Science: Polymer Symposia
- Publisher
- Wiley
- Published
- 1975-01
- Volume
- 51
- Issue
- 1
- Pages
- 135-153
- ISSN
- 0360-8905 (ISSN-L)
- 1936-0959
- OpenAlex
- W2098279377
- Cited by
- 1,094
- References
- 63
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 34 · 2023: 35 · 2022: 30 · 2021: 35 · 2020: 50 · 2019: 36 · 2018: 29 · 2017: 46 · 2016: 45 · 2015: 47 · 2014: 55 · 2013: 43 · 2012: 48
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Polymer Science Polymer Symposia (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Advanced Polymer Synthesis and Characterization
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Keywords
- macromolecular drugs, comonomer incorporation, polymer-analogous reactions, solubility, toxicity, body distribution, polymer synthesis, biological activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.